Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A phase III RCT with adequate design and sample size reporting survival and QoL benefits for homeopathy, but the original publication was retracted by the journal in November 2025 after corrections, with majority co-author disagreement, creating fundamental uncertainty about the reliability and interpretation of these findings.
This is a narrative review synthesizing preclinical mechanistic evidence and clinical trials of variable quality, without presenting a new primary result; it raises questions about acupuncture's role in CIPN rather than answering them with definitive data.
A methodologically sound single-centre internal validation study of prognostic nomograms with good discrimination (C-index 0.74–0.76) in a contemporary HER2-positive metastatic cohort, but limited by lack of specific treatment annotation and short median follow-up relative to the 5-year outcome estimates.
Early-stage preclinical and animal study demonstrating analgesic efficacy of thymoquinone in paclitaxel-induced neuropathy, but with limited structural neuroprotection and no human data, requiring confirmation before clinical translation.
Single-centre retrospective study of 141 patients with observational outcomes; no randomised comparator, no prospective design, and no hard clinical endpoints with effect sizes reported.
Systematic review and meta-analysis of 197 studies with 72,794 patients providing a pooled prevalence estimate with confidence interval; rigorous methodology but epidemiological rather than intervention-based evidence.